All In Biotech

Drug Trial Radar · NCT06072326

dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation

Individual and Combined Endothelin Receptor and SGLT2 Antagonism in Adults With Type 1 Diabetes Mellitus and Chronic Kidney Disease: a Phase 2, Multicenter, Open-label Randomized Cross-over Trial

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Jan 2027

Primary completion

Jan 2029

Study completion Jan 2030

Sponsor

Lead sponsor
University Medical Center GroningenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Juvenile Diabetes Research Foundation; Biocity Biopharmaceutics Co., Ltd.
First posted
Oct 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to test the hypothesis that dapagliflozin (SGLT2 inhibitor) and SC0062 (ERA) combination therapy augments nephroprotection and mitigates fluid retention and ketogenesis in people with T1D through complementary and synergistic mechanisms of actions.

Conditions

  • Type 1 Diabetes Mellitus With Diabetic Nephropathy

Interventions

  • Dapagliflozin (Forxiga®)Drug

    5 mg/day as a tablet

  • SC0062 strength 10mgDrug

    20 mg/day, once daily, 2 capsules of 10 mg

  • SC0062 and dapagliflozinDrug

    20 mg/day, once daily, 2 capsules of 10 mg, in combination with 5 mg/day dapagliflozin 5 mg as a tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Urine Albumin-Creatinine Ratio (UACR)Time frame: From randomization to end of study (V10) up to approximately 24 weeks

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Steno Diabetes Center Aarhus

    Aarhus, Denmark

  • Steno Diabetes Center Copenhagen

    Copenhagen, Denmark

  • Regionshospitalet Gødstrup

    Herning, Denmark

  • Turku University Hospital

    Turku, Finland

  • University of Helsinki

    Helsinki, Uusimaa, Finland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.